308 related articles for article (PubMed ID: 30448598)
1. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
Ahn SH; Kim W; Jung YK; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Yim HJ; Lee KS; Lim YS; Lee WS; Park NH; Jin SY; Kim KH; Choi W; Han KH
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1850-1859.e4. PubMed ID: 30448598
[TBL] [Abstract][Full Text] [Related]
2. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial.
Song DS; Kim W; Ahn SH; Yim HJ; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Jung YK; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Lee KS; Lim YS; Lee WS; Yang JM; Kim KH; Han KH; Um SH
Clin Mol Hepatol; 2021 Apr; 27(2):346-359. PubMed ID: 33493393
[TBL] [Abstract][Full Text] [Related]
3. Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
Yim HJ; Kim W; Ahn SH; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Jung YK; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Lee KS; Lim YS; Lee WS; Han KH
Am J Gastroenterol; 2020 Aug; 115(8):1217-1225. PubMed ID: 32355123
[TBL] [Abstract][Full Text] [Related]
4. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir
Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
[TBL] [Abstract][Full Text] [Related]
11. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
[TBL] [Abstract][Full Text] [Related]
12. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
[TBL] [Abstract][Full Text] [Related]
13. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
Yim HJ; Kim W; Ahn SH; Jung YK; Um SH; Sohn JH; Jang JY; Kim DJ; Park ES; Jin SY; Kim KH
J Gastroenterol Hepatol; 2022 Feb; 37(2):378-386. PubMed ID: 34653281
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
15. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
[TBL] [Abstract][Full Text] [Related]
17. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.
Murray KF; Szenborn L; Wysocki J; Rossi S; Corsa AC; Dinh P; McHutchison J; Pang PS; Luminos LM; Pawlowska M; Mizerski J
Hepatology; 2012 Dec; 56(6):2018-26. PubMed ID: 22544804
[TBL] [Abstract][Full Text] [Related]
18. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.
Lim YS; Lee YS; Gwak GY; Byun KS; Kim YJ; Choi J; An J; Lee HC; Yoo BC; Kwon SY
Hepatology; 2017 Sep; 66(3):772-783. PubMed ID: 28370419
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.
Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Kim K; Kitrinos KM; Subramanian GM; McHutchison JG; Yee LJ; Elkhashab M; Berg T; Sporea I; Yurdaydin C; Husa P; Jablkowski MS; Gane E
J Hepatol; 2017 Jan; 66(1):11-18. PubMed ID: 27545497
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.
Hou JL; Gao ZL; Xie Q; Zhang JM; Sheng JF; Cheng J; Chen CW; Mao Q; Zhao W; Ren H; Tan DM; Niu JQ; Chen SJ; Pan C; Tang H; Wang H; Mao YM; Jia JD; Ning Q; Xu M; Wu SM; Li J; Zhang XX; Ji Y; Dong J; Li J
J Viral Hepat; 2015 Feb; 22(2):85-93. PubMed ID: 25243325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
